Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.9MCash on Hand
8.4mo Cash Runway
Follow QNTM by emailGet an email when QNTM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QNTM, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Earnings Quantum BioPharma reported Q3 2026 results with cash and digital assets of US$12.22 million, shareholders' equity up 91% to US$9.77 million, and operating expenses down 32% for the nine months. It also signed a Study Start-Up Agreement with Thermo Fisher for the Lucid-MS Phase 2 trial after FDA IND clearance. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Shareholder vote Shareholders re-elected all five nominees and approved the auditor, an MVS issuance authority, an omnibus equity plan, a share consolidation of up to 10-to-1, and a name change. Separately, 26 Class A Multiple Voting Shares were sold at C$3.11 each for gross proceeds of C$80.86. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Shareholder vote Quantum BioPharma filed a supplement to its September 28, 2026 circular ahead of the November 10, 2026 shareholder meeting. It corrects fractional share rounding for the proposed share consolidation and says the MVS holders' voting power will be capped at 70% if Class B shares are cancelled. Form 6-K · SEC filing · Press release
Oct 8, 2026 ·
Legal Court consolidated the company's direct action with a shareholder class action alleging spoofing-based manipulation of its shares by CIBC and RBC, and appointed Grant & Eisenhofer as lead counsel. The ruling is procedural and not a finding on the merits. Form 6-K · SEC filing · Press release
Oct 6, 2026 ·
Deal Signed a Study Start-Up Agreement with Thermo Fisher's clinical research business, PPD, to implement the Phase 2 Lucid-MS trial in progressive multiple sclerosis, following FDA clearance to proceed. The trial is randomized, double-blind and placebo-controlled. No financial terms were disclosed. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Leadership Licensee Unbuzzd Wellness appointed Michael Zapolin as CEO, tasked with financing and listing Unbuzzd on a stock exchange and a nationwide U.S. rollout. Predecessor Richard Buzbuzian is assisting the transition. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Rodman & Renshaw initiated coverage of Quantum BioPharma with a BUY rating and a US$8 price target. The company states it paid no fees for the unpaid report. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Financing Quantum BioPharma furnished press releases covering a 7,692-warrant cancellation and 7,692 option grant to director Michael Zapolin at C$6.60, a debenture tranche closed March 6, 2025 for $100,000, debt settlements via Class B shares in July 2026, and new marketing engagements. Most items are administrative. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · N/A · Results Expected · Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis Registry primary completion date, not a results date
Feb 2026 · Phase 4 · Results Expected · Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® XL for the Restoration and/or Augmentation of Facial Volume Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® L in Correcting Moderate or Severe Nasolabial Folds Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® M in Lip Augmentation Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® S in the Correction of Moderate or Severe Infraorbital Hollowing Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not QNTM's own candidates): Ramipril.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
QNTM holds $3.9M in cash and short-term investments and burns about $1.4M/quarter from operations,
an estimated runway of 8.4 months at that rate (BioRadar estimate, not company guidance).
Share count 12 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full QNTM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNTM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.